News
26 November 2021
Gurutz Linazasoro has been awarded a 2021 Korta Award
The CEO of VIVEbiotech, Gurutz Linazasoro, has received one of the four 2021 Korta Awards delivered this past Wednesday by the Lehendakari Iñigo Urkullu.
Read more28 October 2021
Successful participation of VIVEbiotech in five international meetings in the last half of the year
VIVEbiotech has participated very successfully in five international meetings since the summer.
Read more22 October 2021
Juan Carlos Ramírez, CSO/CTO of VIVEbiotech, forever in science and in our hearts
VIVEbiotech colleagues have lived a very painful week due to the death of our colleague and friend Juan Carlos Ramírez.
Read more28 July 2021
Video-report about VIVEbiotech in El Exportador
The digital magazine ‘El Exportador’, edited by ICEX Spain Exports and Investments -the Spanish Institute for Foreign Trade-, has published a video-report on VIVEbiotech as...
Read more7 July 2021
VIVEbiotech obtains the seal of a Company Committed to Youth Employment
This seal is a recognition to VIVEbiotech for its commitment to the Comprehensive Qualification and Employment Program.
Read more23 June 2021
New publication in Cell and Gene Therapy Insights
VIVEbiotech publishes an article entitled “Lentiviral vectors: key challenges and new developments” in the journal Cell and Gene Therapy Insights.
Read more4 June 2021
VIVEbiotech launches lentiviral vector manufacturing plant for cell and gene therapy sector
VIVEbiotech’s production capacity will increase by 400%, with an increase in average batch size per year from 20 in 2020 to 80 in 2022.
Read more27 April 2021
Report about VIVEbiotech in El Confidencial
On the occasion of being a finalist for the 2020 Pyme Award, Banco Santander has made known the great work we do at VIVEbiotech manufacturing lentiviral...
Read more18 March 2021
VIVEbiotech participates in the “V. Professional Training Forum in biotech companies”
FP/Parke is an initiative that aims to arouse the interest of the youngest in technological professions with the collaboration of leading companies in the...
Read more26 February 2021
DEFACTO selects VIVEbiotech to include it in its project
The marketing and communication consultancy DEFACTO has selected VIVEbiotech as a chameleon company that has known how to adapt to the COVID-19 crisis.
Read moreDestacadas
4 March 2024
Spanish researchers to design proteins using AI to make advanced therapies more efficient
20 February 2024
Scrip Citeline Commercial reports VIVEbiotech’s predictions for 2024
14 February 2024
VIVEbiotech forecasts significant growth in lentiviral vectors and CAR-T therapies for 2024
13 February 2024
9 February 2024